InsidersTradesSigma
Track the Absci Corp share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Absci Corp has recorded 96 reports. Market capitalisation: €1.4bn. The latest transaction was disclosed on 6 July 2026 (Acquisition). Among the most active insiders: Jonasson Zachariah. All data is free.
96
Insider Decl.
n/a
Thresholds
€2m
16 ops.
Buy Volume
€13m
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Absci Corp Strong Buy (bullish), based on 9 analysts. Average price target: US$13.78.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 July 2026
Declarations96 total
12,900 shares@ US$11.540.0076% mcap100.0% of flowCommon StockSEC:0001672688-26-000124:0
Canonical exit: 28 Sept 2026 (T+90)
59,896 sharesCommon StockSEC:0001672688-26-000121:0
10,100 shares0Common StockSEC:0001672688-26-000113:0
10,100 shares0Common StockSEC:0001470831-26-000526:0
10,100 shares0Common StockSEC:0001672688-26-000105:0
10,100 shares0Common StockSEC:0001672688-26-000106:0
10,100 shares0Common StockSEC:0001672688-26-000108:0
10,100 shares0Common StockSEC:0001672688-26-000109:0
8,319 shares@ US$6.750.0051% mcap7.4% of flowCommon StockSEC:0001672688-26-000093:0
100,000 shares@ US$2.2955.7% of flowCommon StockSEC:0001672688-26-000049:0
Canonical exit: 10 Jun 2026 (T+90)
406,200 shares0Common StockSEC:0001672688-26-000051:0
49,600 shares0Common StockSEC:0001672688-26-000054:0
90,300 shares0Common StockSEC:0001672688-26-000058:0
135,400 shares0Common StockSEC:0001672688-26-000056:0
5,800 shares0Common StockSEC:0001672688-26-000043:0
90,300 shares0Common StockSEC:0001672688-26-000040:0
406,200 shares0Common StockSEC:0001672688-26-000038:0
49,600 shares0Common StockSEC:0001672688-26-000037:0
135,400 shares0Common StockSEC:0001672688-26-000036:0
1,257 shares@ US$2.800.8% of flowCommon StockSEC:0001672688-26-000035:0
26,761 shares@ US$2.990.013% mcap28.3% of flowCommon StockSEC:0001672688-26-000027:0
17,496 shares@ US$2.990.0084% mcap13.3% of flowCommon StockSEC:0001672688-26-000028:0
8,307 shares@ US$2.743.3% of flowCommon StockSEC:0001672688-26-000029:0
75,095 shares@ US$2.7444.7% of flowCommon StockSEC:0001672688-26-000026:0
Canonical exit: 28 May 2026 (T+90)
396,399 shares@ US$1.2151.9% of flowCommon StockSEC:0001672688-26-000021:0
25 of 96 declarations
关于 Absci Corp
Absci Corp (股票代码: ABSI) 是一家在美国纳斯达克交易所上市的公司。对于法语投资者而言，它最好被视为一家处于生成式人工智能和药物发现交叉点的小盘医疗保健/生物技术公司。该公司自称是一家临床阶段的生物制药公司，专注于通过人工智能原生平台结合可扩展的湿实验室能力来设计差异化抗体疗法。其总部位于华盛顿州温哥华，在纽约市和塞尔维亚设有AI研究实验室，并在瑞士楚格设有创新中心。([investors.absci.com](https://investors.absci.com/?utm_source=openai)) Absci 的公司历史可追溯到2011年8月，当时它作为一家俄勒冈州有限责任公司成立。后来于2016年成为一家特拉华州有限责任公司，并于2020年重组为一家特拉华州公司。这一发展路径与一家风险投资支持的深度科技公司演变为公共生物技术平台业务的模式一致。如今，Absci 的核心价值主张是其“AI药物创造”平台，该平台结合了生成模型、抗体工程、多参数优化和实验验证，以加速生物制剂发现并提高候选药物质量。([sec.gov](https://www.sec.gov/Archives/edgar/data/1672688/000162828022023604/absci-sx3.htm?utm_source=openai)) 在运营方面，公司正在推行两种互补的战略。首先，它正在推进自己的内部专有资产管线。最引人注目的项目是ABS-101，一种用于炎症性肠病的抗TL1A抗体，以及ABS-201，一种针对雄激素性脱发的抗催乳素受体抗体，并有可能扩展到子宫内膜异位症。其次，Absci 与制药、生物技术、科技和学术合作伙伴合作，验证其平台能力并将其商业化。这种内部管线加外部合作的双重模式是其投资案例和竞争定位的核心。([investors.absci.com](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-fourth-quarter-and-full-1?utm_source=openai)) 在竞争方面，Absci 仍然是一家早期公司，运营规模有限，没有成熟的商业产品收入。其差异化在于有望缩短生物制剂发现时间、降低成本并提高成功概率。尽管如此，投资案例仍然高度依赖执行，临床结果、合作成功和资本纪律都可能驱动市场情绪。最近的里程碑意义重大：2025年，Absci 报告了ABS-101的1期研究和ABS-201的1/2a期研究首次给药；2026年，它将ABS-201扩展到子宫内膜异位症，并继续强调其管线进展。与Oracle和AMD合作加速AI驱动的药物发现也凸显了公司的技术雄心。([investors.absci.com](https://investors.absci.com/news-releases/news-release-details/absci-announces-first-participants-dosed-phase-1-clinical-trial/?utm_source=openai))
